Inozyme: Up on UK, U.S. nod for human trials of mineralization disorder drug

Inozyme Pharma

04/01/2021 14:54

** Shares of the biopharmaceutical co  INZY.O  rise 4.2% to
$21.52 in morning trade 
    ** Announces authorization in U.S. and UK for
early-to-mid-stage clinical trials of drug INZ-701 to treat
ENPP1 deficiency - a rare mineralization disorder  urn:newsml:reuters.com:*:nGNX8KrtbK
    ** U.S. FDA clears co's investigational new drug application
for INZ-701
    ** ENPP1 deficiency is a genetic in-born error of metabolism
caused by mutations in ENPP1 gene
    ** Co to enroll first subject in H1 2021 
    ** Expects to provide preliminary safety and biomarker data
in H2 2021

 (Reporting by Sanjana Shivdas in Bengaluru)
 ((SanjanaSitara.Shivdas@thomsonreuters.com; within U.S. +1 646
223 8780, outside U.S. +91 80 6749 1642; Twitter:
@SanjanaShivdas;))